TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04258254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal
Description: Multimodal intervention will involve hello songs, warm up mainly involve sensory and stretching games, music time involves playing instruments, moving game involves use of music or songs to move the whole body, yoga involves themes/songs to perform yoga poses, and good bye involves a goodbye song and reflections about the session. In all movement conditions, trainers emphasize complex and multilimb coordination (asymmetrical and ipsi/contralateral movements) and balance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General
Description: The general exercise group will begin with hello games/set up and end with reflections and cleanup. Children will engage in limb and body warmup routines, specific strengthening exercises (single-joint/single-limb/symmetrical), moderate intensity endurance exercises involving various obstacle courses, and a cool down routine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The seated play group will also begin with hello/icebreaker games and end with goodbye and cleanup. In between, they will read books and review the story line and overall message and engage in fine-motor activities involving building supplies and art-craft.
Study: NCT02465879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapist Triage
Description: An extended role occupational or physical therapist will triage each subject in the study to determine the urgency of their case and how soon they need to see the rheumatologist.
Study: NCT03460496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced practice nurses' interventions
Description: The APN will participate in comprehensively planning individual discharge, coordinating services, consulting with other healthcare professionals, assessing needs on a case by case basis, and coaching the family from birth to 6 months after discharge from the NICU. The APN will provide the Newborn Behavioral Observation (NBO), an infant-centred and family-focused method for building relationships, to parents and children, during and after hospitalization. The NBO helps sensitize parents to their infant's competencies and capabilities, teaching them to read their infant's signals and understand their behaviours. It promotes positive interactions between parent and preterm infant. The APN will also offer telephone support and follow-up Visits at home after discharge.
Study: NCT01074437

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone (Corticosteroid)
Description: Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone (Corticosteroid)
Description: Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Propranolol
Description: Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Liquid placebo will be given during the two month treatment trial.
Study: NCT01956071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WAPD
Description: The objective was to assess workers' acceptability of the Pennington Pedal Desk.
Study: NCT02835937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-Transfuse
Description: Patients will not receive an otherwise-indicated red blood cell transfusion
Study: NCT03060343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zeushield Cytotoxic T Lymphocytes
Description: Three dose levels will be evaluated. Dose Level One: 1.0×10\^5 cells/kg, Dose Level Two: 1.0×10\^6 cells/kg, Dose Level Three: 1.0×10\^7 cells/kg.~At the discretion of the investigator, if patients with active disease have stable disease or a response at week 8 or on subsequent evaluations, they are eligible to receive up to 6 additional infusions at 8 to 12 week intervals.
Study: NCT04494945

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biospecimen Collection
Description: Undergo collection of saliva sample

Intervention type: OTHER
Group type: OTHER
Intervention: Genetic Counseling
Description: Receive genetic counseling if testing results are positive

Intervention type: OTHER
Group type: OTHER
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: OTHER
Group type: OTHER
Intervention: Survey Administration
Description: Complete a survey
Study: NCT01275755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5945 0.25 mg
Study: NCT01013844

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Self Examination Information and ABCDE Rule
Description: Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter \> or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Self Examination Information and ABCDE Rule
Description: Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter \> or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.
Study: NCT03926052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate
Description: Participants randomly assigned to this arm will receive 12 weeks of LDX medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
Study: NCT02316899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Description: Oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide
Description: Oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration once daily
Study: NCT04558567

Intervention type: DRUG
Group type: OTHER
Intervention: Vogelxo
Description: 50mg (1 tube, 5g gel) to 100mg (2 tubes, 10g gel)
Study: NCT03692325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
Study: NCT04466397

Intervention type: DEVICE
Intervention: 3D printed individualized porous implants
Description: Use 3D printed individualized porous implants to reconstruct the large bone defects caused by tumor, infection or trauma.
Study: NCT03750305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imagery-focused Cognitive Therapy
Description: In depth identification phase: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus.~Imagery interventions: The imagery intervention consists of metacognitive imagery rescripting or promoting positive imagery or competing tasks (or a combination of these).~Consolidation: Consist of fine tuning the strategies, relapse prevention using a video diary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Psycho-education is offered in groups, using the format described by Honig (Postma, Honig, \& van Gent, 2008).
Study: NCT02469077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 week aerobic exercise intervention
Description: Participants randomly assigned to the 6 week aerobic exercise intervention will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks).~Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
Study: NCT02309177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Study: NCT04042350

Intervention type: OTHER
Intervention: Non-interventional
Description: Exploring clinical risk factors associated with the risk for cardiovascular events and mortality, rather than to evaluate specific drugs.
Study: NCT02375555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Mobilization
Study: NCT04197674

Intervention type: OTHER
Intervention: Dialysis modality
Description: This is a observational cohort study, and there is no intervention for all participants. Our aim is to evaluate dialysis modality (PD and HD) on patient survival

Intervention type: OTHER
Intervention: Dialysis modality
Description: This is a observational cohort study, and there is no intervention for all participants. Our aim is to evaluate dialysis modality (PD and HD) on patient survival
Study: NCT03415789

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler echocardiogram exam
Description: A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance
Description: A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Magnetic Resonance
Description: A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Coagulation blood test
Description: 5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
Study: NCT04446195

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Intervention
Description: In this study, patients with the risk factors of insufficient intestinal preparation were treated with individualized intervention (mainly from the following aspects: chronic constipation, intestinal preparation not strictly in accordance with the requirements, body mass index \> 25 kg / m2, age \> 70 years old, with other diseases such as diabetes, Parkinson's disease, history of stroke or spinal cord injury, etc., application of tricyclic antidepressants or anesthetics).
Study: NCT03683186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ralinepag
Description: Active
Study: NCT02677038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT04314531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TILD
Description: one 1 mL injection of study medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo injections
Description: one 1 mL injection of placebo
Study: NCT03896529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticipatory psychological stress
Description: Unpredictable delivery of low-level electrical stimulation to left ankle periodically throughout psychology tasks (virtual navigation). Established procedure for inducing anticipatory stress.
Study: NCT05830981

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: 3 months of educational intervention (Lectures, information bulletin, handbook and hardcopy presentation slides) among professionals and patients.
Study: NCT02810470

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel Compact Protein
Description: Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel Compact Protein
Description: Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel Cream
Description: Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel Cream
Description: Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
Study: NCT02541669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-491
Description: TAK-491 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-491
Description: TAK-491 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-491
Description: TAK-491 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-491
Description: TAK-491 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-491 placebo
Description: TAK-491 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-491 placebo
Description: TAK-491 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-491 placebo
Description: TAK-491 placebo-matching tablets
Study: NCT00343785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic bone marrow transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04421560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Capsule, taken by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given as an intravenous injection through a vein (IV) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given as infusion into a vein (intravenous, IV)
Study: NCT03837366

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity tracker and health coaching
Description: Use of an activity tracker alone or in combination with health coaching on physical activity behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity tracker and health coaching
Description: Use of an activity tracker alone or in combination with health coaching on physical activity behaviors.
Study: NCT01486472

Intervention type: DRUG
Intervention: S-1
Description: Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
Study: NCT01562301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 by vein 7 days after Anvirzel administration in a 21 dayc cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by vein 7 days after Anvirzel administration in a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anvirzel
Description: Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.~Expansion Cohort Starting Dose: Maximum tolerated dose from

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
Study: NCT01684579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Group Counseling
Description: The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.